- Home
- BIAF vs NXTS Comparison
BIAF vs NXTS Comparison
Compare BIAF & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | NXTS |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | Israel |
| Employees | 57 | 9 |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BIAF | NXTS |
|---|---|---|
| Price | $0.70 | $2.64 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 559.5K | ★ 2.4M |
| Earning Date | 05-14-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.55 |
| 52 Week High | $13.50 | $23.80 |
Technical Indicators
Market Signals| Indicator | BIAF | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 24.49 | 39.12 |
| Support Level | $0.69 | $0.55 |
| Resistance Level | $0.87 | $6.40 |
| Average True Range (ATR) | 0.05 | 0.51 |
| MACD | 0.03 | -0.28 |
| Stochastic Oscillator | 33.58 | 0.26 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.